Lyme disease bacteria eradicated by new drug in early tests (scopeblog.stanford.edu)

Article summary

Researchers at Stanford Medicine have found that the drug azlocillin can eliminate the bacteria that cause Lyme disease in lab mice and cultures. The study provides evidence that azlocillin can kill both the actively replicating and semi-dormant forms of the bacteria, as well as drug-tolerant persisters. Lyme disease is a common vector-borne disease that affects over 300,000 people in the US each year, and current treatments do not work for up to 20% of patients. Further research is needed to determine the effectiveness of azlocillin in humans.

Main themes

• Lyme disease treatment
• antibiotic effectiveness
• persistent infection
• scientific evidence
• medical research
• COVID-19 prevention

What commenters say

• Some commenters argue that there is no concrete evidence that Lyme spirochetes survive a course of standard antibiotics, and that the idea of persistent infection is not supported by scientific evidence.
• Others suggest that the existence of persistent symptoms in some patients could be due to various factors, including the possibility of drug-tolerant bacteria.
• The effectiveness of azlocillin in killing Lyme bacteria in lab tests is seen as a promising development, but some commenters caution that more research is needed to confirm its efficacy in humans.
• There is disagreement about the interpretation of scientific studies and the validity of different testing methods, such as xenodiagnosis and PCR.
• Some commenters express skepticism about the idea that lingering spirochetes are responsible for persistent symptoms, citing the lack of direct evidence.
• Others argue that the evidence for persistent infection is indirect, but still compelling, and that more research is needed to fully understand the mechanisms of Lyme disease.
• The use of masks as a preventative measure for COVID-19 is also discussed, with some commenters arguing that they are effective and others claiming that they are not.
• There is a call for more nuanced and evidence-based discussions of the effectiveness of different treatments and preventative measures for Lyme disease and other illnesses.